Project Grant R21AI202288
Award Date 8/7/26
Completion Date 7/31/28
Dollars Obligated $210K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $816,016 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic research on type 2 memory B cells and their role in allergy persistence. The research examines how germinal center-derived CD73+CD80+ IgG1 memory B cells generate high-affinity IgE plasma cells upon reactivation through sequential switching, and investigates human IgG...
- The National Institute of Allergy and Infectious Diseases awarded The Feinstein Institutes for Medical Research $460,625 on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the maturation and maintenance of the germinal center niche, specifically follicular dendritic cells (FDCs). The research determines FDC longevity and turnover in young and aged mice at steady state, post-immunization, and under chronic lupus inflammatory conditions,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $464,750 to Icahn School of Medicine at Mount Sinai on July 7, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project completion period extending through June 30, 2027. The award supports research focused on understanding and modulating T cell plasticity, specifically the transdifferentiation of TH17 cells into regulatory T cells...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $832,773 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance an "induce-and-clear" therapeutic strategy targeting HIV-1 latent cellular reservoirs. The research integrates RNA-based latency reversal with engineered high-avidity antibodies to overcome barriers to immune clearance of persistent HIV infection. The project...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $156,510 on March 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on how hepatocytes and skeletal myocytes shape immunity to mRNA-lipid nanoparticle-encoded protein. The research addresses off-target mRNA uptake and expression in hepatocytes and skeletal myocytes during mRNA-LNP delivery. The investigator will engineer...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $462,000 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop FAB-fragment drug conjugates for targeted immunosuppression in organ transplant recipients. The recipient will design and optimize an FAB-fragment drug conjugate platform for selective delivery of the calcineurin inhibitor tacrolimus and the anti-metabolite mycophenolic acid...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map HIV reservoir establishment in human tonsil organoids. The research will characterize nonproductively infected cells—those harboring integrated HIV proviruses that express no viral proteins and thus evade clearance by antiviral treatments and the immune system—as a barrier to HIV...
- Federal Grant Award Summary Icahn School of Medicine at Mount Sinai received a $929,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 23, 2025, with completion targeted for June 30, 2027. The grant supports research investigating the mechanisms of action of messenger ribonucleic acid (mRNA)-based and Newcastle Disease Virus (NDV)-based vaccine platforms in...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $838,493 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize human cytomegalovirus neutralizing monoclonal antibodies as therapeutic biologics. The research characterizes pre-clinical parameters for developing human CMV neutralizing monoclonal antibodies targeting envelope proteins as therapeutics to inhibit CMV infection and...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Icahn School of Medicine at Mount Sinai $868,915 on September 1, 2026, for Project Grant R01AI193023 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research investigates the role of ANKEF1, a ciliary protein, in host defense against influenza virus infection. The work combines novel mouse models, human induced pluripotent stem cell-derived...